Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard Post History

by everswann


V.TLN

RE: RE: RE: RE: RE: RE: Pet Scan Biomarker and int

Re think about this one buddy.You will see that sickness and stupidity are...

February 5, 2009

V.TLN

M2PK - 232 the only drug around for it

http://www.scheringstiftung.de/lang-en/deutsch/programme/wissenschaft...

February 5, 2009

V.TLN

Kinase research

http://www.cancerquest.org/index.cfm?page=404 Downstream mecanism of action ...

February 5, 2009

V.TLN

Current discusion

70 million is about what other deal have got for earlier stage companies (PI...

February 5, 2009

V.TLN

Industry Trend

Roche buying PI oncology drug company http://www.roche.com/media/media...

February 5, 2009

V.TLN

RE: RE: RE: RE: Pet Scan Biomarker and interim res

There is about 20 readers on this board.One of em is managementand 2 others...

February 5, 2009

V.TLN

RE: RE: Pet Scan Biomarker and interim results

Liar, liar, liar.... that is boring. For the PET-SCAN. I will judgewhen I...

February 5, 2009

V.TLN

RE: RE: Weird thing...

Pepman what sorry looser you are.Wait  a minute, unamed expression of...

February 5, 2009

V.TLN

Pet Scan Biomarker and interim results

Pepman what is wrong with you?you must be a freaking liar not to know this...

February 5, 2009

V.TLN

Here the deal

You buy a stock cheap and u hope for positive event to come along. There 6...

February 4, 2009

V.TLN

RE: RE: RE: RE: RE: RE: RE: Valuations - compare T

http://www.thallion.com/docs/publications/18.2007-DrugDiscovery-Dev-updated...

February 4, 2009

V.TLN

RE: RE: RE: RE: RE: RE: Valuations - compare TLN w

No lie on my part because six patients with stable disease is not a proof of...

February 4, 2009

V.TLN

RE: RE: RE: RE: Valuations - compare TLN with Exel

Pepman said:I was aware of those "results". (admission of falsely...

February 4, 2009

V.TLN

Biotech sector revirew

About 30-50% of listed biotech companies will be running out of cash this...

February 4, 2009

V.TLN

RE: RE: RE: RE: Valuations - compare TLN with Exel

Pepman, read this: http://www.thallion.com/en/news-events/press-release...

February 4, 2009

V.TLN

RE: RE: Valuations - compare TLN with Exelixis

Pepman said this : "There is no data of human efficacy for their...

February 4, 2009

V.TLN

RE: RE: Pet scan delays...

Yup management could off taken the offer and it would have been a friendly...

February 3, 2009

V.TLN

Pet scan delays...

LAst conference call on Oct. 2008For 4601According to management, human pet...

February 3, 2009

V.TLN

Valuations - compare TLN with Exelixis

http://www.exelixis.com/pipeline.shtml The closest similar company is...

February 3, 2009

V.TLN

3 compounds 4 partnership deal possible

http://www.thallion.com/en/drug-development/pipeline.php (not up to date...

February 3, 2009

USER FEEDBACK SURVEY ×

Be the voice that helps shape the content on site!

At Stockhouse, we’re committed to delivering content that matters to you. Your insights are key in shaping our strategy. Take a few minutes to share your feedback and help influence what you see on our site!

The Market Online in partnership with Stockhouse